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Objective. IL-23 is a pro-inflammatory cytokine proposed to be central to the development of autoimmune disease. We investigated whether
IL-23, together with the downstream mediator IL-17A, was present and functional in RA in humans.
Methods. RA synovial cells were cultured in the presence or absence of antibodies directed against IL-23p19 or -23R and -17. IL-23, -12, -17,
and their receptors, and IL-6, -1  and TNF-  were measured by ELISA and/or PCR.
Results. Small amounts of cell-associated IL-23 (median 110pg/ml) were detected in RA synovial cultures, and found to be functional as
IL-23R blockade resulting in a significant inhibition of TNF-  (57%), IL-1  (51%) and IL-6 (30%). However, there was a considerable variability
between individual patient samples, and anti-IL-23p19 was found to be considerably less effective. IL-17A protein was detected in  40% of
the supernatants and IL-17A blockade, in IL-17A-producing cultures, resulted in a small but significant inhibition of TNF-  (38%), IL-1  (23%)
and IL-6 (22%). Addition of recombinant IL-23 to cultures had a variable effect on the spontaneous production of endogenous IL-17A with
enhancement observed in some but not all cultures, suggesting that either the low levels of endogenous IL-23 are sufficient to support
cytokine production and/or that the relevant Th17 cells were not present.
Conclusions. These results suggest that although IL-23 may have pathogenic activity in a proportion of patients with late-stage RA, it is not
abundantly produced in this inflammatory tissue, nor does it have a dominant role in all patient tissues analysed.
KEY WORDS: IL-23, IL-17, Rheumatoid arthritis, Anti-IL-23p19, Anti-IL-23R, Synovium, Cytokine.
Introduction
IL-23 is a heterodimeric pro-inflammatory cytokine, secreted by
activated dendritic cells (DCs) and macrophages [1], that binds
to memory T cells, NK cells, macrophages and DCs. IL-23 is
composed of the p19 and the p40 subunits that it shares with
the Th1 cytokine IL-12. The IL-23 and -12 receptors are also
heterodimers, which share the  1 chain (IL-12R 1). The IL-12
receptor utilizes the  2 chain (IL-12R 2), whereas the IL-23
receptor uses the unique IL-23 receptor subunit (IL-23R) [2].
IL-12 induces the development of Th cells that secrete IFN- ,
whereas IL-23 preferentially stimulates the recently defined Th17
subset that produces IL-17A, -17F, -6, -22, TNF-  and GM-CSF
[3–5]. Additionally, IL-23-activated macrophages produce IL-1 
and TNF-  [6].
IL-12p40 knockout mice are resistant to autoimmune pathol-
ogy [7, 8]. More recent studies have shown that mice lacking p19
subunit (lacking IL-23) and mice lacking the p40 subunit (lacking
both IL-12 and -23) were protected from experimental auto-
immune encephalomyelitis [6] and CIA, whereas mice lacking
the p35 subunit (deficient in only IL-12) developed more severe
disease [6, 9, 10], suggesting that IL-23 rather than -12 is patho-
genic. Evidence that IL-23 may be important in human inflam-
matory diseases was shown in psoriasis, where the p19 and p40
subunits were expressed in affected, but not unaffected skin [11]
and in inflamed tissue in Crohn’s disease [12, 13]. The IL-23R gene
had a highly significant association with Crohn’s disease and
ulcerative colitis [14], although no associations with IL-23p19,
-12R 1 or -12p40 were identified. Furthermore, recent genetic
evidence suggests that IL-23R is also a significant determinant
of the co-occurrence of IBD and psoriasis as well as PsA and
AS [15–17]. However, studies on RA cohorts have not shown a
strong association between the IL-23R haplotypes seen in other
chronic inflammatory diseases [18, 19].
IL-17A is the signature pro-inflammatory cytokine produced
by Th17 cells. In mice, Th17 differentiation is dependent
upon TGF-  and IL-6, whereas recent papers suggest that
IL-23, pro-inflammatory cytokines and TGF-  are all required
for differentiation of mature human Th17 cells from naı¨ve cord
blood cells. This is in contrast to previous studies that used adult
cells which suggested that IL-23 was sufficient for IL-17 induction
[20, 21]. In human gut mucosa, inhibition of TGF-  resulted in
up-regulation of several cytokines including IL-17 [22], suggesting
that IL-17 is at least partially regulated by TGF-  in human cells.
IL-17A has pleiotrophic effects on many cell types where it
induces up-regulation of NFkB, HLA class I and cytokines
[23, 24]. Th17 cells are found in RA synovial tissue and IL-17A
protein found in RA SF and SM culture supernatants, where it
acts in synergy with IL-1  and TNF-  [25–29]. Th17 cells function
as the major osteoclastogenic Th cell subset that links T-cell acti-
vation and bone destruction [30], although a recent paper [31]
suggested that IL-23 may drive osteoclastogenesis in an IL-17-
indepenedent manner through the induction of RANK ligand.
CIA is markedly suppressed in IL-17( / ) mice [32], and treat-
ment of CIA mice with an anti-IL-17 antibody after disease onset
significantly reduced joint inflammation of cartilage and bone [33].
We explored the IL-23/-17A pro-inflammatory axis in human
RA using synovial tissue obtained from joint replacement therapy,
which, by definition, indicated that all patients had late-stage
active disease. The message and protein levels of IL-23p19,
-12p35, -12p40, -17A and their receptors were measured using
dissociated cell cultures from these RA synovial tissues. The
modulatory effect of neutralizing anti-IL-17A, -23p19 and -23R
antibodies on spontaneous cytokine production was addressed.
We show that small amounts of biologically active cell-associated
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at even lower levels (which are biologically active). Blocking
IL-23R or -17A had modest, but significant, inhibitory effects
on pro-inflammatory cytokines, whereas blocking IL-23p19 was
even less effective. Importantly, blockade of IL-23R resulted in
total inhibition of IL-17 in those RA synovial cultures where IL-
17 was detected. In contrast, addition of IL-23 to synovial cultures
did not significantly augment the production of IL-17A. These
results indicate that contrary to our expectation, IL-23 was not
found abundantly in these RA synovial cultures, and that the
small amounts of IL-23 present were ‘cell-associated’ and not
secreted. Furthermore, although blocking IL-23R was efficacious
in down-regulating the key inflammatory cytokines, the inhibition
of the p19 subunit of IL-23 was less effective than the neutralizing
IL-23R antibody. These findings are in keeping with both the
small amounts of IL-23 present, and the ‘cell-associated’ nature
of this cytokine in this tissue.
Materials and methods
Human tissue and reagents
Synovial tissue from patients with inflammatory arthritis
undergoing joint replacement surgery was collected after written
consent. Ethical approval was granted by the Riverside Research
Ethics Committee. Synovial membrane samples were digested
using collagenase and DNase as previously described [34]. The
synovial cultures were incubated in Roswell Park Memorial
Institute (RPMI)/glutamine (PAA Laboratories, Pasching,
Austria) with 10% Fetal Calf Serum (FCS) (Biowest, Nuaille ´ ,
France) and 1% penicillin/streptomycin (Sigma, Poole, UK) for
48h at 1 10
6/ml in the presence or absence of 10 g/ml of anti-
TNF-  monoclonal antibody (Infliximab, Centocor, Horsham,
PA, USA), anti-IL-23p19, -23R, -17A and appropriate isotype
control antibodies [mouse IgG1, rat IgG2a and rat IgG1 (BD
Pharmingen, Oxford, UK), respectively]. In some experiments,
recombinant IL-23 or -17A proteins were added. Unless otherwise
stated, all antibodies and recombinant proteins were from
Schering-Plough Biopharma (Palo Alto, CA, USA).
Supernatants were collected for ELISA analysis, cells were
lysed using real life technologies buffer (Qiagen, Valencia, CA,
USA) and 1% 2-mercaptoethanol (Sigma) and analysed for
mRNA by quantitative PCR. It is not feasible to use ‘normal’
synovium as a comparator, as there is very limited availability
of such tissue (obtained after trauma surgery), and that tissue
which is obtained contains very few cells [35].
Generation of antibodies
Monoclonal antibodies against human IL-23R, -23p19 and -17A
were developed at Schering-Plough Biopharma and were all
shown to be specific.
IL-23 bioassay
The murine B cell line (Ba/F3) transfected with IL-12R 1 and
-23R was grown in RPMI containing 25mM HEPES, glutamine
(PAA Laboratories), 10% FCS, 1% penicillin/streptomycin,
10ng/ml murine IL-3 (Schering-Plough Biopharma) and 50 M
2-mercaptoethanol. Cells were plated at 5 10
3 cells/well in
96-well flat-bottomed tissue culture plates (Falcon, Meylan,
France) with mIL-3 (0.06pg/ml to 10ng/ml), human IL-23
(1pg/ml to 200ng/ml) or RA culture supernatants diluted
30-fold. Proliferation was tested with 5ng/ml IL-23 and 0.0625–
10 g/ml anti-IL-23p19 or -23R. [
3H] thymidine (Amersham
Biosciences, Amersham, UK) was added at 1mCi/well for the
final 6h of the 48-h incubation. Plates were harvested (Tomtec
cell harvester, Hamden, CT, USA) and proliferation was quanti-
fied using a Wallac Microbeta scintillation counter (Perkin Elmer,
Beaconsfield, UK).
ELISA
TNF- , IL-6, -1  (BD Pharmingen) and IL-17A (R&D Systems,
Abingdon, UK) in supernatants were measured by ELISA follow-
ing the manufacturer’s instructions. IL-23 protein (rather than the
individual subunits) in the supernatants and lysates (lysed using
0.5% NP-40 in Tris–HCl followed by three freeze–thaw cycles)
was measured using coating anti-IL-12p40 monoclonal antibody
(Diaclone, Besancon, France) and rat anti-human IL-23p19
monoclonal antibody 12F12 (Schering-Plough Biopharma) for
detection. The limit of detection of the TNF-  ELISA was
>10pg/ml; IL-6>13pg/ml; IL-1 > 13pg/ml; IL-23>50pg/ml;
and IL-17A >10pg/ml.
Real-time quantitative PCR
Total RNA was isolated using the RNeasy method (Qiagen), and
5 g was treated with DNase (Roche Molecular Biochemicals,
Indianapolis, IN, USA) reverse-transcribed using Superscript II
(Invitrogen, Carlsbad, CA, USA). Primers were designed using
Primer Express (PE Biosystems, Foster City, CA, USA), or
purchased from Applied Biosystems (Foster City, CA, USA).
Real-time quantitative PCR on 10ng of cDNA was done using
either of two methods; two gene-specific unlabelled primers were
utilized at 400nM in an Applied Biosystems SYBR green real-
time quantitative PCR assay utilizing an ABI 7000, 7300 or
7900 instrument; two unlabelled primers at 900 nM each were
used with 250nM of FAM-labelled probe (Applied Biosystems)
in a TAQMAN
TM real-time quantitative PCR reaction on an ABI
7000, 7300 or 7700 instrument. The absence of genomic DNA
contamination was confirmed using primers that recognize the
CD4 genomic promoter. Ubiquitin levels were used for normal-
ization by the  Ct method: using the mean cycle threshold
values, the equation 1.8e (Ct ubiquitin Ct gene of interest) 10
4
was used to obtain the normalized values.
Immunohistochemistry
Cryostat sections of 5 M of synovial tissue were cut, fixed in
acetone and endogenous peroxidase activity was blocked with
hydrogen peroxide in methanol. Normal horse serum (10%)
(Serotec, Oxford, UK) in Tris-buffered saline (TBS) was used to
block for 10min, and non-neutralizing anti-IL-23p19 antibody
added at 3 g/ml or non-neutralizing anti-IL-23R (both from
Schering-Plough Biopharma) added at 2.06 g/ml for 1h.
Sections were washed in TBS and biotinylated secondary antibo-
dies (Vector Labs, Peterborough, UK) were added, and stained
with avidin–biotin complex (Vector Labs) with diaminobenzidine
added for 5min. Slides were counterstained with haematoxylin,
dehydrated, cleared and mounted.
Phenotyping of RA synovial mononuclear cell population
Cells were stained for CD3, -14, -45 and HLA-DR (Becton-
Dickinson, Franklin Lakes, NJ, USA), and results were expressed
as per cent positive cells. IL-23R and -12R 1 chains were stained
using the non-neutralizing biotinylated IL-23R antibody
(Schering-Plough Biopharma) or biotinylated IL-12R 1 antibody
(R&D Systems) and detected with streptavidin PE (BD
Pharmingen). IL-23p19 antibodies are not currently available for
flow cytometric staining. Cells were acquired and analysed using
the LSR1 flow cytometer with CellQuest software (Becton-
Dickinson) andFlowjo foranalysis (Treestar, Ashland, OR, USA).
Results
Synovial tissue was obtained from a cohort of 20 patients with a
diagnosis of RA (ACR 1987) and from three further patients; two
with juvenile idiopathic arthritis (JIA) and one with PsA. Mean
duration of disease was 18 years indicating advanced-stage dis-
ease. Patients required joint replacement, or corrective surgery
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than one DMARD. Inflammatory markers were generally low,
with ESR values (where available) <20mm/h in the majority of
patients; although three RA patients (Donors 1, 13 and 23) had
elevated ESR (>20mm/h) or CRP (>12mg/dl) levels at the time
of surgery, suggesting more active disease (Table 1).
IL-23 and -17A cytokine and receptor mRNA and protein
levels in RA synovium
Expression levels of each of the subunits of IL-23, -12, -17A and
their receptors in the synovial cultures were determined by real-
time quantitative PCR (Table 1). Results are expressed as median
(interquartile range) relative to ubiquitin. IL-23p19 message was
found at high levels [87.3 (6.8–1627)], whereas p40 message was
very low [0.1 (0–2)]. IL-23 protein was unexpectedly not detected
in the synovial culture supernatants by ELISA (sensitivity of
50pg/ml). In contrast, all cell lysates produced detectable levels
of IL-23 [110 (57–229) pg/ml] (Fig. 1A) indicating that it is
produced by synovial cells, but not secreted at high levels
(unlike other macrophage-derived cytokines). This does not
exclude the possibility that small amounts of IL-23 (<50pg/ml)
are secreted and/or that IL-23 is predominantly cell bound.
GM-CSF-differentiated macrophages produced 400–600pg/ml
IL-23 in lysates, but only  50pg/ml was secreted into the
supernatants (data not shown). The secreted IL-23 protein
increased (up to 300pg/ml) upon toll-like receptor (TLR) ligation
with LPS, and/or R848 with >600pg/ml in the lysates. This sug-
gests that  10-fold more IL-23 protein is found in cell lysates
compared with secreted IL-23 (again, suggesting that the IL-23
is surface bound), and in comparison with other macrophage-
derived cytokines (e.g. TNF- ), picogram but not nanogram
amounts of IL-23 are produced.
IL-17A message has been detected in some, but not all,
synovial membrane biopsies [26, 36]. In our synovial cultures,
IL-17A message was expressed at very low levels [0.03 (0–1.1)]
and was undetectable in 5 of 18 samples (Table 1). Lack of
IL-17A mRNA was also reflected in low levels of IL-17A protein
in culture supernatants as determined by ELISA (detection limit
>10pg/ml). Protein was detectable in 6 of 16 samples [10 (0–100)
pg/ml] (Fig. 1A). Low levels of IL-17A were also present in syno-
vial lysates from five of seven samples examined [15.2 (3.3–23.1)
pg/ml]. Somewhat surprisingly, in two cultures where protein was
detected in supernatants and lysates, IL-17A mRNA was
undetectable, suggesting that IL-17A transcripts, like some other
T-cell cytokines, could be targeted for rapid degradation. IL-27 is
involved in suppressing Th17 development [37], and low levels of
IL-27 message (Table 2) were detected in alldonors tested [2.1(0.8–
11.8)].
IL-23 receptor message was more variable with low levels
of IL-23R [0.58 (0–3.6)] and moderate levels of IL-12R 1
[9.6 (0.79–35.2)]. High expression of the IL-17A receptors was
observed [152.6 (19.1–348.4) for IL-17RA and 105.9 (10.3–
508.8) for IL-17RC] in synovial cells. No correlations were
found between percentage of CD3, -14 or -45 cells detected by
FACS and any of the cytokine subunits or receptor subunits
detected by mRNA (Spearman test).
The presence and relative abundance of IL-23, and to a lesser
extent IL-23R, in RA synovial tissue was confirmed by staining of
tissue sections. Abundant IL-23p19 was observed in cells in both
the lining layer and interstitium (Fig. 1B) consistent with the
presence of macrophages, whereas IL-23R was less evident by
this methodology and was examined further by flow cytometry
in seven donors (for representative donor see Fig. 1C).
IL-23R and -12R 1 were expressed in freshly isolated SM cells
from all seven donors examined. CD14þ macrophages (mean
positive cells 74 10%) and CD4þ lymphocytes (36 28%)
expressed IL-23R, with lower expression of IL-12R 1 (CD14þ,
27 16%; CD4þ,9 7%) (Fig. 1C). The majority of lymphocyte
staining for IL-23R was on CD45ROþ cells (52 28%) with
fewer (13 11%) CD45ROþ lymphocytes positive for
IL-12R 1þ, suggesting that this might be a limiting factor on
CD45RO cells and that perhaps up to 13% of memory lympho-
cytes have the potential to produce IL-17, since a functional IL-23
receptor is now known to be a marker for IL-17-producing Th17
cells in humans [20]. There are few CD45RA cells in RA SMs
(mean 17% compared with 33% CD45RO), and the expression
of IL-23R on these cells was extremely variable [35 30%
(interquartile range 5–84%)], but an even lower proportion
(15 11%) expressed IL-12R 1. RA synovial fibroblasts
expressed no detectable IL-23 or -23R message or -23 protein
(in supernatants or lysed cells). Synovial culture supernatant
contains bioactive IL-23 protein.
Despite the inability to detect IL-23 in supernatants using
ELISA, we tested for bioactive IL-23 by using the supernatants
TABLE 1. Patient demographics showing age, sex and duration of disease
Patient Age, years Sex Duration, years RhF ESR Joint DMARD TNF-  blockers
1 58 F 19 NA 160 MCP Yes No
2 68 M 8 NA 19 Elbow Yes No
3 70 F 23 NA NA MCP Yes Yes
4 63 F 19 NA 25 MCP No No
5 46 F 17 NA NA Wrist No No
6 59 F 18 NA NA Wrist Yes No
7 35 F 16 Positive 23 Hand Yes No
8 36 M 13 Positive NA Hand Yes No
9 73 F NA NA 13 Knee No No
10 67 F NA Positive 21 Knee Yes No
11 54 M 12 Positive 18 Hip No No
12 39 F 20 Positive 9 Knee Yes No
13 72 F 29 Positive 62 Knee No No
14 59 M 30 Positive 6 Knee Yes No
15
a 65 M 7 Negative 34 Knee No No
16 50 M 13 Positive 14 Hip Yes No
17
b 51 M 48 Negative 15 Knee No No
18 75 F 10 Positive 5 Knee No No
19 58 F 9 Negative 8 Hip No No
20 55 M 5 Negative 15 Hip Yes No
21 53 F 9 Positive 5 Knee Yes No
22
b 41 F 34 NA 41 Wrist No No
23 58 F 20 Positive 48 Hand Yes No
All patients had RA except
apatient with PsA,
bpatients with JIA. Where available, RF status and ESR were obtained, 160 refers to CRP level, Joint indicates source of synovial material; DMARD
indicates more than one drug for >12 months; TNF-  blockers refer to anti-TNF-  biological therapy >12 months. NA: not available.
IL-23 axis in RA 1583FIG. 1. Expression of IL-23, -23R and -17 in RA SMs. Mixed synovial cells were cultured for 48h before lysates were tested for IL-23 heterodimer levels, or supernatants
tested for IL-17A by ELISA as described in ‘Materials and methods’ section (A). Results are expressed as mean of three replicates. Median and interquartile ranges are
indicated. Dotted line indicates limit of sensitivity of ELISA. RA synovial tissue sections were stained using non-neutralizing antibodies directed against the p19 subunit, or
the IL-23R as indicated in ‘Materials and methods’ section (B). Freshly isolated RA SM cells (n¼7) were stained for IL-23R and -12R 1 and cell surface markers, then
analysed by flow cytometry as described in ‘Materials and methods’ section (C). The CD4, -45RA and -45RO populations were analysed from the lymphocyte gate as
determined by forward and side scatter, whereas the CD14 population was determined from the macrophage gate. Per cent of positive cells in each quadrant is indicated.
Data shown are representative plots from one (Donor 4) of seven patients.
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cells. Increasing concentrations of IL-23 protein added to the
BaF/3 cells result in proliferative responses. IL-23 of 10.2pg/ml
induced 3209 250c.p.m. proliferation, whereas unstimulated
cells measured 2039 110c.p.m. and the limit of detection was
2260c.p.m. (0.7pg/ml). Two of seven supernatants induced
proliferation above the limit of detection equivalent to a mean
of 47.5pg/ml after allowing for dilution factors (2406 
74c.p.m.). This is consistent with small but functional amounts
of IL-23 produced by the synovial cells, but notably were only
found in two of the RA synovial cell supernatants. This induced
proliferation was reduced to below background levels after addi-
tion of a neutralizing anti-IL-23p19 antibody (1986 17c.p.m.).
DC and GM-CSF-differentiated macrophage supernatants also
demonstrated IL-23-specific bioactivity, but only after stimulation
with TLR ligands (data not shown).
Effect of anti-IL-23R and -23 antibodies
IL-23R and -23p19 blocking antibodies were added to the RA
synovial cultures to examine whether the predominantly ‘cell-
associated’ IL-23 protein contributed to the inflammatory
cytokine cascade (Tables 3 and 4, Fig. 2). Significant inhibition
in TNF-  message (P<0.02) from median 35–16 U was observed
(Table 3), reflected in 57% inhibition (P<0.001) of mean TNF- 
protein levels (Table 4) following treatment with anti-IL-23R in
comparison to a mock treatment control (‘cells only’) (Fig. 2).
Similar inhibition in IL-1  message (Table 3) was observed in
anti-IL-23R-treated cultures with 1748 U compared with 9655
(P<0.008) in the mock controls. This too was reflected in mean
protein levels with a 51% inhibition (P<0.005) (Table 4, Fig. 2).
IL-6 message levels were inhibited from 38218–24698 U [not sig-
nificant (NS)] reflected in a smaller (30%) but still significant
(P<0.02) inhibition of IL-6 protein (Table 4, Fig. 2). We also
included a rat IGg2a isotype control (for the rat anti-IL-23R) in
addition to the mock control, and in these experiments significant
TABLE 2. Cytokine and cytokine receptor mRNA expression in freshly
isolated mononuclear cells from rheumatoid synovium
Cytokine Median (interquartile range)
IL-23p19, n¼20 87.3 (6.8–1627)
IL-23R, n¼16 0.6 (0–3.6)
IL-12p40, n¼13 0.1 (0–2.0)
IL-12p35, n¼17 4.7 (0.1–24)
IL-12R 1, n¼17 9.6 (0.8–35.2)
IL-12R 2, n¼17 3.8 (0–135.4)
IL-17A, n¼18 0.03 (0–1.1)
IL-17RA, n¼17 153 (19.1–349)
IL-17RC, n¼14 106 (10.3–509)
IL-27, n¼7 2.1 (0.8–11.8)
Cytokine mRNA expression of IL-23p19 and -23 receptor, IL-12p35, common chain
p40, IL-12 receptor ( 2) and common receptor chain ( 1), IL-27 and -17A together with
IL-17 receptor units A and C were assessed by Taqman PCR as described in ‘Materials
and methods’ section in freshly isolated synovial membrane mononuclear cells from
patients with RA. Results are expressed relative to ubiquitin.
TABLE 3. Modulatory effect of blockade of IL-23 receptor or IL-23p19 upon pro-inflammatory cytokine mRNA expression in cultured RA mononuclear synovial membrane
cells
Cells only, median rtIgG2a isotype, median anti-IL-23 receptor, median
P-value
msIgG1 isotype, median Anti-IL-23p19, median
P-values
(interquartile range) (interquartile range) (interquartile range) Cells IgG2a (interquartile range) (interquartile range) Cells IgG1
TNF-  35 (7–328) 59 (7–230) 16 (2–104) 0.02 0.008 52 (5–91) 42 (1–132) NS NS
IL-1  9655 (748–69350) 14802 (669–52746) 1748 (172–17835) 0.008 0.02 3304 (767–20854) 9457 (424–30105) NS NS
IL-6 38218 (1913–144868) 28562 (2579–98435) 24698 (7–80739) NS NS 71841 (14718–10835) 24308 (2749–103525) NS NS
IL-23p19 80 (7–684) 68 (4–971) 18 (5–456) NS NS 52 (5–1308) 63 (1–119) NS NS
Effect of anti-IL-23R or -23p19 neutralizing antibodies on pro-inflammatory cytokine mRNA levels (units relative to ubiquitin) compared with cells only (n¼8, except p19 where n¼5). Cells were
harvested 48h after culture, and mRNA was prepared as described in ‘Materials and methods’ section. P-values were calculated using a Wilcoxon signed rank test and compared with either cells only
or with the appropriate isotype control.
TABLE 4. Modulatory effect of IL-23 receptor or p19 blockade upon spontaneous cytokine production in RA synovial membrane cultures
TNF- , pg/ml IL-1 , pg/ml IL-6, ng/ml
Donor Cells only Anti-IL-23R Anti-IL23p19 Cells only Anti-IL-23R Anti-IL23p19 Cells only Anti-IL-23R Anti-IL23p19
1 408 (47) 250 (5) 367 (54) 13 (4) 12 (10) 10 (1) 96 (10) 55 (17) 69 (4)
2 782 (13) 526 (56) 647 (110) 55 (2) 13 (1) 27 (1) 347 (12) 10 (1) ND
3 680 (2) 567 (10) 593 (25) 116 (4) 72 (1) 89 (2) 235 (19) 222 (22) 196 (22)
4 6373 (740) ND 4331 (238) 279 (28) ND 179 (12) 128 (14) ND 110 (16)
5 432 (6) 381 (24) 534 (48) 170 (4) 106 (12) 121 (13) 645 (71) 818 (32) 590 (45)
6 122 (51) 115 (29) ND 94 (17) 34 (14) 58 (21) 192 (14) 132 (35) 85 (29)
7 966 (140) 613 (31) 983 (68) 141 (23) 68 (8) 92 (26) 62 (5) 56 (4) 64 (11)
8 1759 (198) ND 50 (23) 117 (23) ND 106 (23) 987 (145) ND 661 (24)
13 1713 (244) 20 (1) 847 (122) 216 (70) 20 (1) 136 (13) 79 (3) 78 (4) ND
14 UN UN UN 105 (13) 20 (1) ND UN UN UN
15 UN ND UN 83 (28 43 (14) ND 888 (321) 66 (7) ND
16 2163 (128) 1596 (165) 2046 (86) 247 (72) 63 (10) 232 (67) 1028 (127) 832 (112) 757 (97)
17 UN UN UN 26 (9) 20 (1) 20 (1) 584 (16) 80 (17) 529 (117)
18 560 (92) ND 533 (50) 129 (35) ND 78 (21) 223 (7) ND 198 (17)
19 1159 (20) 817 (5) 801 (13) 28 (7) 14 (0.4) 15 (8) 944 (109) 768 (3) 689 (120)
20 1993 (556) 1243 (156) 1866 (688) 909 (34) 593 (70) 921 (89) 1067 (323) 1012 (43) 887 (139)
21 493 (50) 474 (38) 192 (159) 31 (12) 26 (8) ND 868 (67) 620 (52) 615 (128)
n 14 11 13 17 14 17 16 13 13
Mean 1400 1572 600 471 1053 1145 162 207 79 151 149 231 524 389 365 378 419 303
Median 875 526 648 116 30 91 466 132 529
Interquartile range 122–6373 20–1596 50–4331 13–909 12–593 10–921 63–1067 10–101 265–887
P-value 0.001 0.0005 0.0001 0.0009 0.005 0.002
Rheumatoid synovial mononuclear cells were set up in triplicate in culture (anti-IL-23R or -23p19. Supernatants were harvested after 48h and cytokine levels determined by ELISA as described in
‘Materials and methods’ section. Results are expressed as mean (S.D.), median and interquartile range from 17 samples. Statistical analysis was performed using Wilcoxon signed rank or paired t-test
as appropriate after testing for Gaussian distribution of data using a Kolmogorov–Smirnov test. ND: data not available; UN: cytokine undetectable.
IL-23 axis in RA 1585inhibition of TNF-  and IL-1 message and protein was still
observed, with 73% inhibition of TNF-  mRNA (P¼0.02),
88% inhibition of IL-1  mRNA (P¼0.02) (Table 3) and 51%
inhibition of TNF-  protein (P¼0.003) with 44% inhibition of
IL-1  protein (P¼0.007) (data not shown). IL-6 levels, although
reduced, did not reach statistical significance when compared with
the isotype control (Table 3 and data not shown).
In vitro treatment of the synovial cultures with a neutralizing
anti-IL-23p19 was ineffective in this culture system. No significant
changes in message levels of TNF- , IL-1  or -6 were observed
compared with mock treatment or mouse IgG1 isotype controls
(Table 3). Small, but significant, changes in protein levels
(Table 4) were observed with 25% inhibition of TNF-  protein
(P¼0.0005), 17% inhibition of IL-6 protein production
(P¼0.001) and 11% inhibition of IL-1  (P¼0.001) (Table 4)
when compared with mock treatment. When these data were
compared against isotype control-treated cultures (mouse IgG1)
in the four cultures where we had sufficient cells to perform this
control, the modest changes in cytokine levels were even less and
did not reach significance (data not shown).
To investigate whether IL-23 had any impact on its own
production, anti-IL-23R or -23p19 were added to the cultures
and IL-23 message assessed. Anti-IL-23R addition caused a
significant decrease in IL-23p19 mRNA expression (mean 43%;
P¼0.03) from 60 to 18 U (Table 3). Anti-IL-23p19 addition,
however, did not significantly change IL-23p19 message.
IL-17A (Fig. 1) was detectable in 6 of 16 supernatants
(interquartile range of cells only 0–100pg/ml), and was markedly
inhibited either by addition of the anti-IL-23R (interquartile range
0–15pg/ml) but to a lesser extent by addition of the anti-IL-23p19
(interquartile range 0–74pg/ml) (data not shown).
TNF-  has been reported to inhibit IL-12 and -23 production
by mouse macrophages and DCs [38]. However, addition of neu-
tralizing anti-TNF-  antibody to the synovial cultures (n¼8) had
FIG. 2. Cytokine production and mRNA expression in RA SM mononuclear cell cultures: effect of IL-23 blockade. Mixed RA synovial cell cultures were set up in triplicate and
either left untreated or with 10 g/ml anti-IL-23R monoclonal antibody for 48h. Pro-inflammatory cytokines [(A and B) TNF- ;( C and D)I L - 1  ;( E and F) IL-6] in culture
supernatant were quantified by ELISA (B, D, F) and cytokine mRNA by Taqman PCR (A, C, E), both as described in ‘Materials and methods’ section. Data are normalized
to 100% for each of the cells only levels, and per cent change from this is plotted. Median and interquartile range of per cent change is indicated, P-values were calculated
using Wilcoxon signed rank test.
1586 Philippa Hillyer et al.no significant impact on IL-23 protein in cell lysates (data not
shown). Although IL-23p19 mRNA was decreased in each patient
following addition of anti-TNF- , the inhibition did not achieve
statistical significance (P¼0.056 by Wilcoxon signed rank test)
(data not shown).
IL-23R and -23p19 neutralizing antibodies were not ‘toxic’ and
did not promote cell death as determined by MTT assays (100
untreated vs 102% anti-IL-23R treated, n¼3; P¼0.75 by
Wilcoxon signed rank test) and propidium iodide (PI) staining
by flow cytometric analysis (cells only: 8% PI positive; anti-IL-
23R: 11% PI positive; anti-IL-23p19: 10% propidium iodide (PI)
positive; data representative of three experiments).
Effect of neutralizing IL-17A antibody
A neutralizing IL-17A antibody was added to the RA synovial
cultures (n¼10) in order to determine the effect of IL-17A upon
TNF- , IL-1  and -6 production (Table 5). IL-17A had previously
been detected in the supernatant of 5 of these 12 donors (mean
21pg/ml) and in the lysate of four out of six of these donors (mean
17pg/ml). Two donors expressed no detectable IL-17 in lysates or
supernatants. Blockade of IL-17A overall resulted in inhibition of
TNF- , IL-1  and -6 by a mean of 38 (P¼0.002), 23 (P¼0.049)
and 22% (P¼0.03) by Wilcoxon signed rank test in comparison
with mock treatment, respectively. Due to the lack of tissue
availability, isotype controls (rat IgG1) were used in only six of
these samples (data not shown). In these six donors, significant
inhibition of TNF-  (mean 33%; P¼0.03) and IL-1  (mean 35%;
P¼0.03) was shown by Wilcoxon signed rank test, but inhibition
of IL-6 (2%) was not significant.
Effect of addition of exogenous recombinant IL-23
IL-23 promotes expansion of Th17 lymphocytes that produce
IL-17A, -17F, -22, -6 and TNF- , following antigen stimulation
[3]. To examine whether low endogenous IL-23 was limiting IL-17
production, exogenous IL-23 (interquartile range from 0 to
200ng/ml) was added to synovial cultures for 48h and cytokines
in the supernatants determined by ELISA. Recombinant IL-23
induced TNF-  production in 3 of 13 synovial cultures (Patients
4, 6 and 22; Table 1) and IL-17A in one of these three specimens
and in a further two samples (Patients 1, 4 and 8; Table 1) (data
not shown). There were no significant differences in the percen-
tage of CD3þ, -14þ or HLA-DRþ cells from the five subjects
that responded to IL-23 compared with those in which there was
no response.
Discussion
We explored the role of endogenous pro-inflammatory cytokine
IL-23 in RA using ex vivo synovial cell cultures from patients
undergoing joint replacement surgery. The tissue was predomi-
nantly from patients with advanced disease, but was generally
less ‘inflammatory’ than RA synovial joint tissue used in earlier
studies from our group in the 1990s [34, 39–42]. This reduced
inflammatory phenotype is characterized by fewer inflammatory
cells with markedly lower spontaneous production of TNF-  in
some specimens, and has been observed by several researchers in
the field (unpublished data). This change is generally thought to
be due to earlier therapeutic intervention with DMARDs (parti-
cularly MTX) and biological therapies [43], although only one of
our donors (Donor 3) had received anti-TNF-  therapy (Table 1).
IL-23 protein was not detected in the supernatants from these
RA synovial cell cultures (limit of detection  50pg/ml). However,
reasonable IL-23 levels [mean (median) 130 (110) pg/ml] were
detected in cell lysates, suggesting that the IL-23 measured
was either cell-surface bound or intracellular. Owing to lack of
availability of flow cytometry antibodies, this possibility was not
addressed in the current study. However, we suspect that this
IL-23 was bioavailable, since IL-23R blockade significantly inhib-
ited the spontaneous production of IL-1 , TNF-  and, to a lesser
extent, IL-6. IL-23p19 blockade was less effective than the IL-23R
antibody in these cultures. The greater potency of receptor vs
ligand blockade was not expected but has been observed
previously, notably with IFN-  in this RA synovial system
(F.M. Brennan, unpublished data), and possibly reflects the super-
iority of blocking the receptor where the ligand is not abundant
and/or is cell bound. The modulatory effect of the IL-23R anti-
body on cytokine production was not due to non-specific effects,
nor increased apoptosis or cell death as determined by MTT assay
and annexin V analysis. Furthermore, the observation that the
IL-23R antibody was more efficient than the p19 antibody at
blocking TNF-  and IL-1 in these synovial cell cultures is not
due to affinity, as both antibodies had a similar affinity (pM)
for their respective ligands and both inhibited IL-23-mediated
proliferation of transfected BAF cells, IFN production by
human splenocytes and STAT3 phosphorylation.
It was somewhat surprising that IL-23, which is
produced by macrophages and DCs, was not more abundant in
these RA synovial cultures. However, low levels of the IL-23
heterodimer (assessed by immunohistochemistry) in synovial
tissue samples from patients with RA were also reported recently
[44], and in another recent report [45], which despite indicating a
strong association of systemic IL-23 in RA with disease activity,
TABLE 5. Modulatory effect of IL-17 blockade upon spontaneous cytokine production in RA SM mononuclear cell cultures
TNF- , pg/ml IL-1 , pg/ml IL-6, ng/ml
Patient Cells only Anti-IL-17 Cells only Anti-IL-17 Cells only Anti-IL-17
1 646 (11) 628 (54) 22 (3) 24 (13) 27 (1) 14 (7)
4 2300 (238) 1586 (73) 160 (23) 85 (5) 291 (47) 217 (23)
5 1784 (155) 204 (110) 1320 (105) 903 (68) 2334 (157) 1894 (354)
6 361 (64) 264 (8) 38 (5) 25 (6) 530 (36) 461 (11)
7 2801 (125) 2445 (27) 210 (47) 165 (31) 643 (25) 465 (2)
8 1759 (198) 201 (208) 117 (23) 106 (45) 987 (164) 561 (130)
16 2163 (128) 2035 (271) 247 (72) 240 (98) 1028 (224) 718 (160)
18 560 (92) 370 (6) 129 (35) 55 (9) 223 (35) 190 (25)
20 67 (24) 10 (1) 342 (69) 402 (56) 589 (37) 715 (64)
23 488 (77) 334 (24) 74 (15) 31 (10) 235 (2.1) 165 (13)
Mean 1293 971 808 876 266 383 204 273 689 664 540 532
Median 1202 352 144 95 559 464
Interquartile range 67–2801 10–2445 22–1320 24–903 27–2335 14–1894
P-value 0.002 0.049 0.03
Rheumatoid synovial mononuclear cells were set up in triplicate in culture anti-IL-17. Supernatants were harvested after 48h and cytokine levels were determined by ELISA as described in
‘Materials and methods’ section. Results are expressed as mean (S.D.), median and interquartile range from 12 samples. Statistical analysis was performed using Wilcoxon signed rank test or paired t-
test as appropriate after testing for Gaussian distribution of data using a KS test.
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these patients was also very low (mean 20pg/ml). It is possible
that homoeostatic mechanisms can effectively control IL-23 pro-
duction, and reports (somewhat paradoxically) have described
that TNF-  negatively regulates IL-23 (and IL-12) in mouse anti-
gen-presenting cells during an inflammatory response [38]. Anti-
TNF-  addition to the RA synovial cell cultures, however, did not
increase IL-23 cell-associated levels; whereas a reduction (non-
significant) in p19 mRNA levels was observed. It is not known
how much IL-23 is necessary to initiate and maintain a response in
inflamed human tissue. Since IL-23 can drive a highly pathogenic
response, and is an important key cytokine for Th17 differentia-
tion and proliferation in human cells [20, 21], it is likely that its
expression is tightly regulated and may never reach levels similar
to those seen for other inflammatory cytokines.
Based on our current understanding of IL-23 biology, the
expectation was that the pathogenic effects of IL-23 would be
mediated by its downstream effector IL-17A [3, 4, 46, 47]. Small
amounts of IL-17A protein were found in  40% of the culture
supernatants [mean (median) 23 (10) pg/ml] (levels consistent with
previous published studies [25, 26]). Other cytokines, such as
IL-27, may inhibit Th17 differentiation [48], and in our study,
IL-27 message was found at low but detectable levels [2.1
(0.8–11.8)], raising the possibility that it may exert homoeostatic
control over Th17 differentiation in this tissue. In our study,
blockade of IL-17A significantly inhibited the spontaneous
production of TNF- , IL-1  and -6 in the synovial cell culture,
but was less effective than IL-23R blockade indicating that IL-23
pathogenic effects were not induced exclusively via IL-17A. Since
IL-17A exerts its pathology in synergy with macrophage-derived
cytokines including TNF-  and IL-1  [28, 49], it is not surprising
that IL-17A is not always dominant in RA synovium and likely
that the relative contributions of IL-17A, TNF- , IL-1  or -6 are
variable between patients. Furthermore, other unique Th17 cell
products, such as IL-17F, -21 and -22, may be involved in the
inflammatory processes controlled by IL-23.
Addition of IL-23, however, to the cultures did not significantly
enhance spontaneous production of endogenous IL-17A. A full
dose interquartile range (from 0 to 200mg/ml) of IL-23 was tested.
Since there are few naı¨ve T cells in rheumatoid SMs and cells are
only cultured for a 48h, it is unlikely that significant ‘new’ Th17
differentiation occurs in response to IL-23 addition. The majority
of lymphocyte staining for the IL-23R was on memory CD45RO
T cells. A much lower percentage of CD45RO cells stained for
IL-12R 1 suggesting that this might be a limiting factor for
response to exogenous IL-23 in these cultures. It is possible that
in these RA tissues, CD45RO cells have selectively lost the expres-
sion of IL-12R 1, as a mechanism to make them less responsive to
IL-23 (and IL-12). However, addition of IL-23 to these cultures
also did enhance spontaneous production of endogenous TNF- 
(only in 3 out of 13 donors). In this case, production of TNF- 
was not limited to the presence of Th17 cells. It is likely
(as observed previously) that in this inflammatory tissue, the
production of pro-inflammatory cytokines is already effectively
maximal, and that further attempts to stimulate cytokine produc-
tion with exogenous stimulation results in only modest effects
increases in cytokine production.
This study demonstrates that small amounts of cell-associated
IL-23 are present in rheumatoid tissue and that IL-23 regulates
IL-17A and macrophage-derived cytokines, IL-6, -1  and TNF- .
Neither IL-23 nor IL-17A appear as dominant in human RA as
might have been predicted from mouse knockout studies [9, 32],
although it is possible that the IL-23/Th17 immune axis plays a
more dominant role during the onset of disease or in an acute flare
of disease. Of particular note was the observation that in the
synovial cell cultures from Donor 13 which had active disease at
the time of surgery (Table 1) blockade of IL-23R totally inhibited
the TNF-  and IL-1 protein levels. Furthermore, it is not clear
why the IL-23 receptor blockade was more efficacious than
p19 inhibition in our study, as in three different bioassays
(IL-23-driven BAF cell proliferation, IL-23 stimulation of
IFN-  from human splenocytes and IL-23-induced STAT3
phosphorylation) their efficacy was similar. It is possible that
the neutralizing antibody which we used (which was generated
against soluble IL-23) was unable to effectively neutralize the
majority of IL-23 in our cultures that were cell surface-associated.
Irrespective of the mechanism, blockade of IL-23 bioactivity
(via the receptor) in these synovial cultures resulted in a similar
degree of inhibition of IL-1  and -6 production as that observed
previously with the humanized chimeric anti-TNF-  antibody,
cA2 [50]. However, although it is not unreasonable to speculate
that blockade of IL-23 in human RA might be efficacious, the
necessity to block the IL-23 receptor (neutralization of IL-23p19
was ineffective) clearly has limitations.
Clinical trials of anti-IL-23 or -17A in humans have not
yet been reported, but trials of anti-p40 in Crohn’s disease and
psoriasis were shown to be efficacious [51–53]. Of particular inter-
est are the recent findings that SNPs in the IL-12B and -23R gene
and haplotypes are associated with the risk of psoriasis [54–56]
and other inflammatory diseases including Crohn’s disease [14],
ulcerative colitis [57], AS [58] and PsA [59]. However, despite these
observations, several independent studies on patients with RA
have indicated that they do not appear to play a major role in
RA risk [60, 61], suggesting that these variants in the IL-12/-23
pathway may not differentially influence RA pathogenesis. In our
study, there were additional tissues from two patients with JIA
and one with PsA, and in both these samples (data not shown),
blockade of IL-23R or -17A resulted in a similar modest, but
significant, inhibition of TNF- , IL-1  and -6. Whether the invol-
vement of IL-23 and -17A in murine arthritis translates effectively
to human arthritis remains an open question that can only
be answered by clinical trials in humans.
Rheumatology key messages
  Small amounts of cell-associated IL-23 are found in RA synovial
tissue.
  IL-23 regulates endogenous IL-17 production in RA synovial tissue
explants.
  IL-23 is a potential therapeutic target in RA.
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